Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
A phase 3 trial of Prednisone and Apalutamide and Abiraterone acetate in Prostate cancer, run by Dana-Farber Cancer Institute, recorded as terminated on the registry.
Overview
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT is a phase 3 interventional study registered as NCT03777982 by Dana-Farber Cancer Institute, with 12 participants recorded, started 2020-04-20 and due to reach its primary completion in 2024-02-13. Interventions recorded: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist. Conditions recorded: Prostate Cancer.
Linked to the idea "Prescribe a quarter dose of abiraterone with breakfast" because the registry names Prednisone and Apalutamide and Abiraterone acetate among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Shares Prescribe a quarter dose of abiraterone with breakfast, Prednisone, Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Apalutamide, Prednisone, Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Apalutamide, Prostate cancer and the tag pipeline.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Shares Apalutamide, Prostate cancer and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Prednisone, Prostate cancer and the tag pipeline.